A B S T R A C T During the large epidemic of serogroups A and C meninlgococcal disease in Brazil, we studied the immunologic response to meningococcal polysaccharide vaccine in infants bom to women vaccinated during pregnancy. Radioimmunoassay serum levels against serogroups A and C polysaccharide were more than threefold higher in vaccinated than in unvaccinated women at delivery. Cord blood levels were also threefold or higher in infants whose mothers were vaccinated while pregnant compared to infants born of unvaccinated mothers. Within 3 mo, the infants' A and C serum antibody levels declined by -80%. When vaccinated at about 6 mo of age, infants born of vaccinated mothers had antibody responses to A and C polysaccharide vaccines indistinguishable from those born of unvaccinated mothers. The response did not vary with the trimester of vaccination. We conclude that the vaccination of pregnant women with groups A and C meningococcal polysaccharide vaccine does not produce immunie tolerance in the subsequently born infants.
INTRODUCTION
Meningococcal disease continues to occur in epidemic proportions in populations scattered throughout the world (1) (2) (3) (4) . Large epidemics may be a result of serogroup A (2-4) or C (1), whereas endemic disease and focal outbreaks are more often caused by group B (5-7) or C (5, 8) . Milestones in the control of serogroups A and C outbreaks were reached with the licensing of meningococcal serogroups A and C polysaccharide vaccines (9) . In field trials, serogroup C vaccines (10, 11) , This work was initiated while Dr. McCormick and Mr. Gorman were short-term advisors for the Pan American Health Organization.
Received for publication 11 July 1979 and in revised form 14 January 1980. for persons above 2 yr of age, and serogroup A vaccines (12) (13) (14) , for persons over 1 yr, have proven safe, immunogenic, and efficacious. Both vaccines are licensed for the control of epidemic disease in the United States, but the guidelines for usage contain an admonition against giving them to pregnant women (9) . This admonition is supported by animal studies that show pneumococcal polysaccharide vaccine, given to infant mice, produced immune tolerance (15) (16) (17) , and by studies of type I pneumococcal polysaccharide in human infants (18) .
During the years 1974 and 1975, a large epidemic of serogroups A and C meningococcal disease occurred in Brazil (2, 13) . Because of this epidemic, the Brazilian government carried out a countrywide vaccination campaign with serogroups A and C polysaccharide vaccines, which gave us the opportunity to study a mass vaccination program and to observe the immunologic response to meningococcal polysaccharide vaccine (MPV)' in infants born to women vaccinated while pregnant.
METHODS
We interviewed a group ofwomen in Amapa, Brazil the day after they were vaccinated, and identified 51 pregnant women that we would be able to follow through delivery. We bled 25 of these women on the day after they were vaccinated, by jet gun, with an intramuscular dose mixture of 50 .ug of A anid 50 itg of C MPV. The initial vaccine was manufactured by Merieux Co., Lyons, France and was the vaccine used throughout Brazil in the campaign.
We followed these 51 women through delivery, at which time we collected a sample of cord blood. We also collected a cord blood sample from infants of 39 women who had not been vaccinated during the campaign. 39 children of vaccinated mothers were bled at 3 mo, and 31 were bled at 6-8 mo, IAbbreviation used in this paper: MPV, meningococcal polysaccharide vaccine. 
RESULTS
In a group of 25 women from whom serum was collected within 24 h after vaccination, the geometric mean antipolysaccharide A level was 4.98 /gIml, not significantly different from the mean level of 6.37 ug/ml in unvac-einlate(l woivoen lbledl at delivery (Tables I and II) . The mean antibody level at deliverv' for vaccinatedl womeni, in contrast, was 13.43 ug/ml, significanitlv higher thani that level at the time of vaceiniation. Resuilts ofthe serogroup C antibody studies showed the prevaccination levels to be much lower than serogroup A levels, but the rise in antibody after vaccinationi was relatively higher (Table III) .
In both serogroups A and C studies, the cordI serum levels averaged about one-half the mothers' levels at dlelivery, but were significantly higher than controls (7.13 vs. 2.40 gg/mI for A and 2.94 vs. 0.25 ug/ml for serogroup C).
Serogroups A andl C serum antibody levels showe(d 80 and 89% declinies, respectively, fromii birth to 3 mo of age (1.33 ,ug/ml for A and 0.30 ,ug/ml for C). At 6-8 mio of age the antibody levels had further (leclined by sign ificant amounts ancI were, in fact, equal to levels in childrein of the samiie age whose mothers were not vaccinatedl.
The rise in serogroup A meninigococcal antibody after vaccinationi of infanits whose mothers had been vaccinated was 2.6-fold, from 0.62 to 1.57 ,ug/ml (Table I) . This rise was not distinguishable from the 3.1-fold rise (0.57 to 1.78 ,uggml) in a group of controls whose mothers had not been vaccinated. The rise in serogrouip C men ingococcal antibody after vaccination of infants whose mothers had been vaccinated during pregnancy was 6.2-fold (0.16-1.02 ug/ml). The mean rise in antibody in 26 infants of the same age born of unvaccinated mothers was 13.3-fold (0.1-1.80 ,ug/ml). There was no statistical difference between cases and controls as to frequency or magnitude of response. More than 90% of children responded to both A and C vaccines with rises in antibody. None had decreases in antibody to either of the antigens after vaccination. trimester of the mothers' vaccination. Although there were some differences in the responses, all had greater than twofold rises, none of the differences by trimester were statistically significant, however, with the small number of subjects very large differences would be required to see a statistical significance.
We also looked at antibody levels in the mothers and infants at birth by trimester of vaccination, and although there were differences, they were not statistically significant.
No obvious physical abnormalities at birth were noted in our study population.
DISCUSSION
Mechanisms have been described for immune tolerance to assorted polysaccharide antigens (15) (16) (17) . These are more descriptive of events than explanations of processes. Studies have also demonstrated that mice respond poorly to optimal immunizing doses oftype III pneumococcal polysaccharide after a low dose of antigen given 2-25 d before (17) . Furthermore, inadvertent vaccination of humans with trace amounts of serogroup C MPV has resulted in a very poor response to subsequent optimal immunizing doses of serogroup C antigen (20) . All of this experience has justifiably resulted in extreme caution regarding recommendations for giving these vaccines to pregnant women.
Our study shows that children born to mothers vaccinated during gestation, regardless of the trimester ofvaccination, were not immunotolerant to group A and C vaccine at 6 mo of age. Whether this reflects the inability of the polysaccharide to reach the fetus, rather than inability of the polysaccharide to induce immune tolerance, is a matter of speculation.
More than 90% of the children in this study responded to vaccinations with a mixture of 50 ,ug of serogroup C and 25 jig of serogroup A MPV. The proportion of children responding and the magnitude of their response are consistent with other studies ofthese vaccines in infants (14, 21, 22) . In addition, the response to the vaccine was the same in the study populations as in the controls.
Previous studies have shown that antimeningococcal immunoglobulin (G) bactericidal antibody is present in >50% of newborns, usually equal to the level found in maternal serum (23) . Additionally, the antibody levels decline during the first year, to minimnum levels between 6 and 12 mo of age (23) .
A recent study of serogroup A MPV in Finland (14) (22) . In our study, the antibody levels at age 3 mo in children whose mothers were vaccinated during pregnancy were of the same magnitude as the levels attained after vaccination at age 6-8 mo, despite the fact that antibody levels declined >50% from 3 to 6 mo of age. Vaccination of pregnant women, therefore, gives a high antibody level in the newborn that is sustained at levels which may be protective up to and perhaps beyond 3 mo of age. Further, such levels can be reattained and probably sustained throughout most of the first year of life by vaccination at 6 mo of age.
In the face of a meningococcal epidemic it is very desirable to be able to vaccinate the entire population. Indeed, as in Brazil, it is not possible to avoid vaccination of women in early pregnancy. Our study leads us to conclude that precautions against vaccination of pregnant women with licensed meningococcal polysaccharide vaccines during an epidemic should be lifted.
